The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.
To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.
For additional information please review our Privacy Policy.
A series of studies conducted by the General Accounting Office in 1991-92 found that approximately half of the uses of anticancer chemotherapy drugs are for indication other than those reviewed by the Food and Drug Administration and referenced on the FDA-approved label. The “off-label” uses of approved drugs have been an important tool for advancing the treatment of cancer. Third-party payers, including Medicare, typically denied reimbursement for these unlabeled indications on the ground that such uses were experimental or investigational. ASCO's position states that third-party payers should be required to cover off-label indications for anti-cancer drugs if such indications are listed in the compendia or supported in peer-reviewed medical literature.
ASCO's Position:
ASCO's Position for Off-Label Drug Indications
